Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Exclusives

More »
July 18, 2017

Looking at the CAR-T Landscape as First Approval Nears

Sounds of Science Podcast

Looking at the CAR-T Landscape as First Approval Nears

Source: luismmolina/Getty Images

  • AUDIO

    Brad Loncar, CEO of Loncar Investments, discusses the outlook for chimeric antigen receptor T cell (CAR-T) cancer therapies as Novartis nears FDA approval for the first such treatment, CTL019. Some other CAR-T therapies have also shown early, yet promising, clinical data.

Related content